RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers
Disease control Recruiting nowThis study is testing whether adding a new immune-stimulating drug (CDX-1140) to two existing cancer drugs works better for women whose ovarian cancer has returned. About 80 participants will receive either the standard two-drug combination or the new three-drug combination, give…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New Drug-Radiation combo tested for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination treatment for gynecologic cancers that have returned after previous therapy. Researchers are combining an oral drug called talazoparib with standard radiation therapy to see if it works better together. The main goal is to find …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope: using a Patient's own supercharged cells to battle aggressive ovarian cancer
Disease control Recruiting nowThis early-stage study is testing a new personalized treatment for ovarian cancer that has returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, grow and train them in a lab to recognize cancer, and then infuse them back into the patient…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial uses genetic blueprint to find the right drug combo for advanced cancer
Disease control Recruiting nowThis trial is a large screening program that matches patients with advanced solid tumors to one of many smaller treatment studies. It uses genetic testing on a patient's tumor to find specific mutations. Patients are then assigned to a drug combination designed to target those mu…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo tested to control Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis study is for women whose ovarian or endometrial cancer has returned or persisted despite prior treatment and has a specific genetic change (a RAS pathway mutation). It aims to see if taking two targeted drugs (selumetinib and olaparib) together works better than taking just …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Can a smartwatch help fight cancer? study tests personalized exercise plans
Disease control Recruiting nowThis study is testing whether a personalized exercise program, guided by a Fitbit, helps patients with ovarian or endometrial cancer meet the recommended 150 minutes of weekly activity better than standard advice. It aims to see if more exercise improves quality of life, physical…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, pelcitoclax and cobimetinib, for women with ovarian or endometrial cancer that has returned after prior treatment. The main goals are to find the safest and most effective dose and to check for side effects. Resear…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
New scan could spot hidden cancer cells
Knowledge-focused Recruiting nowThis study is testing a new radioactive tracer used in PET/CT scans to see if it can better find and track cancer cells in people with solid tumors, including ovarian, breast, and other cancers. Researchers will inject the tracer and perform scans to see how well it highlights tu…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
Scientists hunt clues to prevent blood cancers in cancer survivors
Knowledge-focused Recruiting nowThis study aims to understand why some people who have been treated for cancers like ovarian cancer later develop blood cancers or disorders. Researchers will observe 2,000 patients who have had certain cancer treatments to look for genetic and other risk factors. They will colle…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC